| Patent application number | Description | Published |
|---|
| 20080226629 | ANTI-VEGF ANTIBODIES - Humanized and variant anti-VEGF antibodies and various uses therefor are disclosed. The anti-VEGF antibodies have strong binding affinities for VEGF; inhibit VEGF-induced proliferation of endothelial cells in vitro; and inhibit tumor growth in vivo. | 09-18-2008 |
| 20080299120 | MULTIVALENT ANTIBODIES AND USES THEREFOR - The present application describes engineered antibodies, with three or more functional antigen binding sites, and uses, such as therapeutic applications, for such engineered antibodies. | 12-04-2008 |
| 20090081707 | Human trk receptors and neurotrophic factor inhibitors - The invention concerns human trkB and trkC receptors and their functional derivatives. The invention further concerns immunoadhesins comprising trk receptor sequences fused to immunoglobulin sequences. | 03-26-2009 |
| 20090137471 | NGF VARIANTS - NGF variants which have trkC-binding activity and trkC-signal inducing activity are provided. The variants optionally have trkA or trkB binding and signal induction activity. The NGF variants of the present invention are useful in the treatment of neuronal disorders. Nucleic acids and expression vectors encoding the NGF variant neurotrophins are also provided. | 05-28-2009 |
| 20090155257 | IMMUNOGLOBULIN VARIANTS AND USES THEREOF - The invention provides humanized and chimeric anti-CD20 antibodies for treatment of CD20 positive malignancies and autoimmune diseases. | 06-18-2009 |
| 20090156788 | ENGINEERED ANTI-IL-23 ANTIBODIES - Engineered antibodies to human IL-23p19 are provided, as well as uses thereof, e.g. in treatment of inflammatory, autoimmune, and proliferative disorders. | 06-18-2009 |
| 20090175881 | ANTIBODIES TO IL-17A - Engineered antibodies to human IL-17A are provided, as well as uses thereof. | 07-09-2009 |
| 20090285810 | HUMANIZED ANTI-TGF-BETA ANTIBODIES - Humanized anti-TGF-beta antibodies are provided, as well as methods for their preparation and use, including methods for treating TGF-beta disorders, for example, cancer. Also provided are articles of manufacture designed for various uses that contain the humanized antibodies. | 11-19-2009 |
| 20100003261 | AGONIST ANTI-TRK-C MONOCLONAL ANTIBODIES - The invention concerns agonist anti-trkC monoclonal antibodies which mimic certain biological activities of NT-3, the native ligand of trkC. The invention further concerns the use of such antibodies in the prevention andior treatment of cellular degeneration, including nerve cell damage associated with acute nervous cell system injury and chronic neurodegenerative diseases, including peripheral neuropathy. | 01-07-2010 |
| 20100016556 | METHOD FOR MAKING HUMANIZED ANTIBODIES - Variant immunoglobulins, particularly humanized antibody polypeptides are provided, along with methods for their preparation and use. Consensus immunoglobulin sequences and structural models are also provided. | 01-21-2010 |
| 20100111966 | ENGINEERED ANTI-IL-23P19 ANTIBODIES - Engineered antibodies to human IL-23p19 are provided, as well as uses thereof, e.g. in treatment of inflammatory, autoimmune, and proliferative disorders. | 05-06-2010 |
| 20100136005 | Method of Treatment Using Humanized Anti-CD11a Antibodies - Humanized anti-CD11 | 06-03-2010 |
| 20100150945 | ANTI-MDL-1 ANTIBODIES - Antibodies to human MDL-1 are provided, as well as uses thereof, e.g., in treatment of immune disorders, in particular, infectious diseases and sepsis. | 06-17-2010 |
| 20100166766 | ENGINEERED ANTI-TSLP ANTIBODY - The invention relates to binding compounds that specifically bind to human TSLP, as well as uses thereof, e.g., in the treatment of inflammatory disorders. | 07-01-2010 |
| 20100166767 | ENGINEERED ANTI-IL-23R ANTIBODIES - Antibodies to human IL-23R are provided, as well as uses thereof, e.g. in treatment of inflammatory, autoimmune, and proliferative disorders. | 07-01-2010 |
| 20100178296 | ANTIBODIES TO CD200R - The present invention relates to binding compounds specific for the human inhibitory CD200R and uses thereof. More specifically, the invention relates to antibodies that recognize the human inhibitory CD200R and modulates its activity in inflammatory and autoimmune disorders. | 07-15-2010 |
| 20100184656 | PANTROPIC NEUROTROPHIC FACTORS - Pantropic neurotrophic factors which have multiple neurotrophic specificities are provided. The pantropic neurotrophic factors of the present invention are useful in the treatment of neuronal disorders. Nucleic acids and expression vectors encoding the pantropic neurotrophins are also provided. | 07-22-2010 |
| 20100203049 | Interleukin-10 Antibodies - The methods and compositions provided herein relate generally to IL-10 specific antibodies and uses thereof. More specifically, compositions of humanized IL-10 specific antibodies and methods to use such antibodies in modulating the biological activity of IL-10, particularly in autoimmune disorders and pathogen-mediated immunopathology. | 08-12-2010 |
| 20100254986 | METHOD FOR MAKING HETEROMULTIMERIC POLYPEPTIDES - The invention relates to a method of preparing heteromultimeric polypeptides such as bispecific antibodies, bispecific immunoadhesins and antibody-immunoadhesin chimeras. The invention also relates to the heteromultimers prepared using the method. Generally, the method involves introducing a protuberance at the interface of a first polypeptide and a corresponding cavity in the interface of a second polypeptide, such that the protuberance can be positioned in the cavity so as to promote heteromultimer formation and hinder homomultimer formation. “Protuberances” are constructed by replacing small amino acid side chains from the interface of the first polypeptide with larger side chains (e.g. tyrosine or tryptophan). Compensatory “cavities” of identical or similar size to the protuberances are created in the interface of the second polypeptide by replacing large amino acid side chains with smaller ones (e.g. alanine or threonine). The protuberance and cavity can be made by synthetic means such as altering the nucleic acid encoding the polypeptides or by peptide synthesis. | 10-07-2010 |
| 20100255013 | GLYCOPROTEIN COMPOSITIONS - The present invention concerns compositions comprising a glycoprotein having an Fc region, wherein about 80-100% of the glycoprotein in the composition comprises a mature core carbohydrate structure which lacks fucose, attached to the Fc region of the glycoprotein. The preferred glycoprotein is an antibody or immunoadhesin. | 10-07-2010 |
| 20100272731 | ENGINEERED ANTI-IL-23P19 ANTIBODIES - Engineered antibodies to human IL-23p19 are provided, as well as uses thereof, e.g., in treatment of inflammatory, autoimmune, and proliferative disorders. | 10-28-2010 |
| 20110002942 | Engineered Anti-IL-23 Antibodies - Engineered antibodies to human IL-23p19 are provided, as well as uses thereof, e.g. in treatment of inflammatory, autoimmune, and proliferative disorders. | 01-06-2011 |
| 20110020369 | ENGINEERED ANTI-TSLPR ANTIBODIES - The invention relates to binding compounds that specifically bind to human TSLPR, as well as uses thereof, e.g., in the treatment of inflammatory disorders. | 01-27-2011 |
| 20110038878 | ANTIBODIES TO IL-17A - Engineered antibodies to human IL-17A are provided, as well as uses thereof. | 02-17-2011 |
| 20110052575 | ANTI-VEGF ANTIBODIES - Humanized and variant anti-VEGF antibodies and various uses therefor are disclosed. The anti-VEGF antibodies have strong binding affinities for VEGF; inhibit VEGF-induced proliferation of endothelial cells in vitro; and inhibit tumor growth in vivo. | 03-03-2011 |
| 20110052596 | ANTIBODIES TO IL-17A - Engineered antibodies to human IL-17A are provided, as well as uses thereof. | 03-03-2011 |
| 20110081342 | ANTI-VEGF ANTIBODIES - Humanized and variant anti-VEGF antibodies and various uses therefor are disclosed. The anti-VEGF antibodies have strong binding affinities for VEGF; inhibit VEGF-induced proliferation of endothelial cells in vitro; and inhibit tumor growth in vivo. | 04-07-2011 |
| 20110086050 | GLYCOPROTEIN COMPOSITIONS - The present invention concerns compositions comprising a glycoprotein having an Fc region, wherein about 80-100% of the glycoprotein in the composition comprises a mature core carbohydrate structure which lacks fucose, attached to the Fc region of the glycoprotein. The preferred glycoprotein is an antibody or immunoadhesin. | 04-14-2011 |
| 20110110852 | Multivalent Antibodies and Uses Therefor - The present application describes engineered antibodies, with three or more functional antigen binding sites, and uses, such as therapeutic applications, for such engineered antibodies. | 05-12-2011 |
| 20110129464 | HUMANIZED ANTI-ERBB2 ANTIBODIES AND TREATMENT WITH ANTI-ERBB2 ANTIBODIES - The present application describes humanized anti-ErbB2 antibodies and methods for treating cancer with anti-ErbB2 antibodies, such as humanized anti-ErbB2 antibodies. | 06-02-2011 |
